Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy: The washington, dc, dilated cardiomyopathy study

Steven Scott Coughlin, Catherine Metayer, Ellen P. Mccarthy, Frances J. Mather, Richard E. Waldhom, Bernard J. Gersh, Stephen Dupraw, Kenneth L. Baughman

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

An epidemiologic study was earned out to examine the possible role of β-agonists and other respiratory medications in the development of idiopathic dilated cardiomyopathy. Associations with respiratory medications, bronchial asthma, emphysema, and chronic bronchitis were examined by comparing newly diagnosed cases (n= 129) ascertained from five Washington, DC, area hospitals for the period 1990-1992 with neighborhood controls (n= 258) identified by using a random digit dialing technique. The cases and controls were matched on sex and 5-year age intervals and were compared in the analysis using conditional logistic regression methods. A statistically significant association was observed between idiopathic dilated cardiomyopathy and history of emphysema or chronic bronchitis (adjusted odds ratio (OR) = 4.4, 95% confidence interval (Cl) 1.6-12.4). The association with bronchial asthma was of borderline significance (adjusted OR = 1.9, 95% Cl 0.9-4.2). Associations were also observed with use of oral β-agonists (adjusted OR= 3.4, 95% Cl 1.1-11.0) and β-agonist inhalers or nebulization (adjusted OR = 3.2, 95% Cl 1.4-7.1), as well as with use of oral corticosteroids, inhaled corticosteroids or cromolyn, and theophylline medications. A total of 20.0% (23 of 115) of the cases had a reported history of β-agonist inhaler use compared with 6.7% (17 of 254) of the controls. The strength of these associations was diminished when the temporal relation between exposure to β-agonist inhalers or oral preparations and clinical diagnosis of idiopathic dilated cardiomyopathy was taken into account, however, and the associations with duration of β-agonist medication use were not statistically significant (p > 0.05). The results of this study suggest, but do not prove, that use of β-agonists has an etiologic role in idiopathic dilated cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)395-403
Number of pages9
JournalAmerican journal of epidemiology
Volume142
Issue number4
DOIs
StatePublished - Aug 15 1995
Externally publishedYes

Fingerprint

Dilated Cardiomyopathy
Nebulizers and Vaporizers
Odds Ratio
Chronic Bronchitis
Emphysema
Adrenal Cortex Hormones
Asthma
Cromolyn Sodium
Theophylline
Epidemiologic Studies
Logistic Models
Confidence Intervals

Keywords

  • Asthma
  • Bronchitis
  • Cardiomyopathy
  • Congestive
  • Emphysema

ASJC Scopus subject areas

  • Epidemiology

Cite this

Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy : The washington, dc, dilated cardiomyopathy study. / Coughlin, Steven Scott; Metayer, Catherine; Mccarthy, Ellen P.; Mather, Frances J.; Waldhom, Richard E.; Gersh, Bernard J.; Dupraw, Stephen; Baughman, Kenneth L.

In: American journal of epidemiology, Vol. 142, No. 4, 15.08.1995, p. 395-403.

Research output: Contribution to journalArticle

Coughlin, Steven Scott ; Metayer, Catherine ; Mccarthy, Ellen P. ; Mather, Frances J. ; Waldhom, Richard E. ; Gersh, Bernard J. ; Dupraw, Stephen ; Baughman, Kenneth L. / Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy : The washington, dc, dilated cardiomyopathy study. In: American journal of epidemiology. 1995 ; Vol. 142, No. 4. pp. 395-403.
@article{37f9aa619ac44370905087eb25ca3aa3,
title = "Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy: The washington, dc, dilated cardiomyopathy study",
abstract = "An epidemiologic study was earned out to examine the possible role of β-agonists and other respiratory medications in the development of idiopathic dilated cardiomyopathy. Associations with respiratory medications, bronchial asthma, emphysema, and chronic bronchitis were examined by comparing newly diagnosed cases (n= 129) ascertained from five Washington, DC, area hospitals for the period 1990-1992 with neighborhood controls (n= 258) identified by using a random digit dialing technique. The cases and controls were matched on sex and 5-year age intervals and were compared in the analysis using conditional logistic regression methods. A statistically significant association was observed between idiopathic dilated cardiomyopathy and history of emphysema or chronic bronchitis (adjusted odds ratio (OR) = 4.4, 95{\%} confidence interval (Cl) 1.6-12.4). The association with bronchial asthma was of borderline significance (adjusted OR = 1.9, 95{\%} Cl 0.9-4.2). Associations were also observed with use of oral β-agonists (adjusted OR= 3.4, 95{\%} Cl 1.1-11.0) and β-agonist inhalers or nebulization (adjusted OR = 3.2, 95{\%} Cl 1.4-7.1), as well as with use of oral corticosteroids, inhaled corticosteroids or cromolyn, and theophylline medications. A total of 20.0{\%} (23 of 115) of the cases had a reported history of β-agonist inhaler use compared with 6.7{\%} (17 of 254) of the controls. The strength of these associations was diminished when the temporal relation between exposure to β-agonist inhalers or oral preparations and clinical diagnosis of idiopathic dilated cardiomyopathy was taken into account, however, and the associations with duration of β-agonist medication use were not statistically significant (p > 0.05). The results of this study suggest, but do not prove, that use of β-agonists has an etiologic role in idiopathic dilated cardiomyopathy.",
keywords = "Asthma, Bronchitis, Cardiomyopathy, Congestive, Emphysema",
author = "Coughlin, {Steven Scott} and Catherine Metayer and Mccarthy, {Ellen P.} and Mather, {Frances J.} and Waldhom, {Richard E.} and Gersh, {Bernard J.} and Stephen Dupraw and Baughman, {Kenneth L.}",
year = "1995",
month = "8",
day = "15",
doi = "10.1093/oxfordjournals.aje.a117647",
language = "English (US)",
volume = "142",
pages = "395--403",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy

T2 - The washington, dc, dilated cardiomyopathy study

AU - Coughlin, Steven Scott

AU - Metayer, Catherine

AU - Mccarthy, Ellen P.

AU - Mather, Frances J.

AU - Waldhom, Richard E.

AU - Gersh, Bernard J.

AU - Dupraw, Stephen

AU - Baughman, Kenneth L.

PY - 1995/8/15

Y1 - 1995/8/15

N2 - An epidemiologic study was earned out to examine the possible role of β-agonists and other respiratory medications in the development of idiopathic dilated cardiomyopathy. Associations with respiratory medications, bronchial asthma, emphysema, and chronic bronchitis were examined by comparing newly diagnosed cases (n= 129) ascertained from five Washington, DC, area hospitals for the period 1990-1992 with neighborhood controls (n= 258) identified by using a random digit dialing technique. The cases and controls were matched on sex and 5-year age intervals and were compared in the analysis using conditional logistic regression methods. A statistically significant association was observed between idiopathic dilated cardiomyopathy and history of emphysema or chronic bronchitis (adjusted odds ratio (OR) = 4.4, 95% confidence interval (Cl) 1.6-12.4). The association with bronchial asthma was of borderline significance (adjusted OR = 1.9, 95% Cl 0.9-4.2). Associations were also observed with use of oral β-agonists (adjusted OR= 3.4, 95% Cl 1.1-11.0) and β-agonist inhalers or nebulization (adjusted OR = 3.2, 95% Cl 1.4-7.1), as well as with use of oral corticosteroids, inhaled corticosteroids or cromolyn, and theophylline medications. A total of 20.0% (23 of 115) of the cases had a reported history of β-agonist inhaler use compared with 6.7% (17 of 254) of the controls. The strength of these associations was diminished when the temporal relation between exposure to β-agonist inhalers or oral preparations and clinical diagnosis of idiopathic dilated cardiomyopathy was taken into account, however, and the associations with duration of β-agonist medication use were not statistically significant (p > 0.05). The results of this study suggest, but do not prove, that use of β-agonists has an etiologic role in idiopathic dilated cardiomyopathy.

AB - An epidemiologic study was earned out to examine the possible role of β-agonists and other respiratory medications in the development of idiopathic dilated cardiomyopathy. Associations with respiratory medications, bronchial asthma, emphysema, and chronic bronchitis were examined by comparing newly diagnosed cases (n= 129) ascertained from five Washington, DC, area hospitals for the period 1990-1992 with neighborhood controls (n= 258) identified by using a random digit dialing technique. The cases and controls were matched on sex and 5-year age intervals and were compared in the analysis using conditional logistic regression methods. A statistically significant association was observed between idiopathic dilated cardiomyopathy and history of emphysema or chronic bronchitis (adjusted odds ratio (OR) = 4.4, 95% confidence interval (Cl) 1.6-12.4). The association with bronchial asthma was of borderline significance (adjusted OR = 1.9, 95% Cl 0.9-4.2). Associations were also observed with use of oral β-agonists (adjusted OR= 3.4, 95% Cl 1.1-11.0) and β-agonist inhalers or nebulization (adjusted OR = 3.2, 95% Cl 1.4-7.1), as well as with use of oral corticosteroids, inhaled corticosteroids or cromolyn, and theophylline medications. A total of 20.0% (23 of 115) of the cases had a reported history of β-agonist inhaler use compared with 6.7% (17 of 254) of the controls. The strength of these associations was diminished when the temporal relation between exposure to β-agonist inhalers or oral preparations and clinical diagnosis of idiopathic dilated cardiomyopathy was taken into account, however, and the associations with duration of β-agonist medication use were not statistically significant (p > 0.05). The results of this study suggest, but do not prove, that use of β-agonists has an etiologic role in idiopathic dilated cardiomyopathy.

KW - Asthma

KW - Bronchitis

KW - Cardiomyopathy

KW - Congestive

KW - Emphysema

UR - http://www.scopus.com/inward/record.url?scp=0029153498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029153498&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.aje.a117647

DO - 10.1093/oxfordjournals.aje.a117647

M3 - Article

C2 - 7625404

AN - SCOPUS:0029153498

VL - 142

SP - 395

EP - 403

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 4

ER -